SCHEMBL13615103

SCHEMBL13615103

Cc1cc(NS(=O)(=O)c2ccc(Cl)cc2)ccc1C(C)(C)C

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.58
CYP19A1 P11511 1/20 0.56
FFAR4 Q5NUL3 2/20 0.54
FFAR1 O14842 1/20 0.54
ALDH1A1 P00352 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
PKM P14618 3/20 0.51
MAPT P10636 2/20 0.50
ATIC P31939 1/20 0.50
GAA P10253 1/20 0.50
ESR1 P03372 1/20 0.49
CDK1 P06493 1/20 0.48
CCNB1 P14635 1/20 0.48
CCNA2 P20248 1/20 0.48
CDK2 P24941 1/20 0.48
CDK7 P50613 1/20 0.48
CCNH P51946 1/20 0.48
CCNA1 P78396 1/20 0.48
PRMT1 Q99873 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13615086 0.89 PKM (0.55) ALDH1A1PKMCDK1CCNB1CCNA2
SCHEMBL13615036 0.88 ALDH1A1 (0.59) CYP19A1FFAR4FFAR1ALDH1A1TDP1
SCHEMBL13615049 0.85 CYTH2 (0.59) FFAR4ALDH1A1PKMGAA
SCHEMBL13852820 0.85 PKM (0.73) ALDH1A1TDP1PKMMAPT
SCHEMBL13615120 0.84 CES1 (0.57) CES1CYP19A1FFAR4FFAR1ALDH1A1
SCHEMBL13615338 0.83 PPARG (0.56) ALDH1A1PKMMAPTCDK1CCNB1
SCHEMBL13615072 0.83 CDK1 (0.63) ALDH1A1TDP1MAPTCDK1CCNB1
SCHEMBL13615044 0.83 PKM (0.72) CYP19A1FFAR4ALDH1A1PKMMAPT
SCHEMBL13615091 0.83 FFAR4 (0.60) FFAR4FFAR1ALDH1A1MAPTCDK1
SCHEMBL7181291 0.79 CES1 (0.62) CES1CYP19A1FFAR4ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK CES1 3083/4885CYP19A1 3011/4885FFAR4 3554/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK CES1 3173/4885CYP19A1 3220/4885FFAR4 3913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.